428 related articles for article (PubMed ID: 31735286)
1. Harnessing the Microbiome for Pancreatic Cancer Immunotherapy.
Vitiello GA; Cohen DJ; Miller G
Trends Cancer; 2019 Nov; 5(11):670-676. PubMed ID: 31735286
[TBL] [Abstract][Full Text] [Related]
2. The Role of the Microbiome in Immunologic Development and its Implication For Pancreatic Cancer Immunotherapy.
Sethi V; Vitiello GA; Saxena D; Miller G; Dudeja V
Gastroenterology; 2019 May; 156(7):2097-2115.e2. PubMed ID: 30768986
[TBL] [Abstract][Full Text] [Related]
3. The microbiota and microbiome in pancreatic cancer: more influential than expected.
Wei MY; Shi S; Liang C; Meng QC; Hua J; Zhang YY; Liu J; Zhang B; Xu J; Yu XJ
Mol Cancer; 2019 May; 18(1):97. PubMed ID: 31109338
[TBL] [Abstract][Full Text] [Related]
4. Microbiota Alterations and Their Association with Oncogenomic Changes in Pancreatic Cancer Patients.
Sammallahti H; Kokkola A; Rezasoltani S; Ghanbari R; Asadzadeh Aghdaei H; Knuutila S; Puolakkainen P; Sarhadi VK
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884776
[TBL] [Abstract][Full Text] [Related]
5. The correlation between gut and intra-tumor microbiota and PDAC: Etiology, diagnostics and therapeutics.
Qian J; Zhang X; Wei B; Tang Z; Zhang B
Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188943. PubMed ID: 37355177
[TBL] [Abstract][Full Text] [Related]
6. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Blair AB; Zheng L
Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
[TBL] [Abstract][Full Text] [Related]
7. Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma.
Pandey V; Storz P
Expert Rev Anticancer Ther; 2019 Jun; 19(6):473-482. PubMed ID: 31148495
[No Abstract] [Full Text] [Related]
8. Harnessing the Microbiome to Enhance Cancer Immunotherapy.
Nelson MH; Diven MA; Huff LW; Paulos CM
J Immunol Res; 2015; 2015():368736. PubMed ID: 26101781
[TBL] [Abstract][Full Text] [Related]
9. The microbiome and hepatobiliary-pancreatic cancers.
Mima K; Nakagawa S; Sawayama H; Ishimoto T; Imai K; Iwatsuki M; Hashimoto D; Baba Y; Yamashita YI; Yoshida N; Chikamoto A; Baba H
Cancer Lett; 2017 Aug; 402():9-15. PubMed ID: 28527946
[TBL] [Abstract][Full Text] [Related]
10. Combination Immunotherapy Approaches for Pancreatic Cancer Treatment.
Cheng X; Zhao G; Zhao Y
Can J Gastroenterol Hepatol; 2018; 2018():6240467. PubMed ID: 29707526
[TBL] [Abstract][Full Text] [Related]
11. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].
Ye C; Zheng L; Yuan CH
Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for pancreatic cancer: present and future.
Aroldi F; Zaniboni A
Immunotherapy; 2017 Jun; 9(7):607-616. PubMed ID: 28595517
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Sahin IH; Askan G; Hu ZI; O'Reilly EM
Ann Oncol; 2017 Dec; 28(12):2950-2961. PubMed ID: 28945842
[TBL] [Abstract][Full Text] [Related]
14. Microbiota in pancreatic health and disease: the next frontier in microbiome research.
Thomas RM; Jobin C
Nat Rev Gastroenterol Hepatol; 2020 Jan; 17(1):53-64. PubMed ID: 31811279
[TBL] [Abstract][Full Text] [Related]
15. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes.
Riquelme E; Zhang Y; Zhang L; Montiel M; Zoltan M; Dong W; Quesada P; Sahin I; Chandra V; San Lucas A; Scheet P; Xu H; Hanash SM; Feng L; Burks JK; Do KA; Peterson CB; Nejman D; Tzeng CD; Kim MP; Sears CL; Ajami N; Petrosino J; Wood LD; Maitra A; Straussman R; Katz M; White JR; Jenq R; Wargo J; McAllister F
Cell; 2019 Aug; 178(4):795-806.e12. PubMed ID: 31398337
[TBL] [Abstract][Full Text] [Related]
16. Complex role for the immune system in initiation and progression of pancreatic cancer.
Inman KS; Francis AA; Murray NR
World J Gastroenterol; 2014 Aug; 20(32):11160-81. PubMed ID: 25170202
[TBL] [Abstract][Full Text] [Related]
17. Exosomes and the Future of Immunotherapy in Pancreatic Cancer.
Batista IA; Melo SA
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699928
[TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.
Smith C; Zheng W; Dong J; Wang Y; Lai J; Liu X; Yin F
World J Gastroenterol; 2022 Jul; 28(27):3297-3313. PubMed ID: 36158269
[TBL] [Abstract][Full Text] [Related]
19. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
[TBL] [Abstract][Full Text] [Related]
20. Novel and emerging innate immune therapeutic targets for pancreatic cancer.
Wang L; Shureiqi I; Stroehlein JR; Wei D
Expert Opin Ther Targets; 2018 Dec; 22(12):977-981. PubMed ID: 30332892
[No Abstract] [Full Text] [Related]
[Next] [New Search]
